BioNexus advances VitaGuard MRD rollout in SE Asia after China visit; targets 2026 deployment

BioNexus Gene Lab Corp

Working visit to Tongshu Gene facilities in Shanghai and Changzhou; reviewed implementation for SE Asia under license.
VitaGuard is a tumor-naive fixed-panel liquid biopsy for MRD; currently in paid commercial use in China.
BioNexus holds exclusive license for 10 SE Asian markets (pop. 680M); also owns ~15% of Fidelion holding international rights.
Target cost per test under $300; initial deployment targeted in select SE Asian medical hubs during 2026.
Fidelion in discussions with partners for markets outside SE Asia; no definitive agreement yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.